Global Anticoagulants Market Analysis and Forecast 2024-2030
Summary
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
According to APO Research, The global Anticoagulants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Anticoagulants include Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson., Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo and Otsuka, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Anticoagulants, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anticoagulants, also provides the revenue of main regions and countries. Of the upcoming market potential for Anticoagulants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anticoagulants revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anticoagulants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Anticoagulants revenue, projected growth trends, production technology, application and end-user industry.
Anticoagulants segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anticoagulants in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anticoagulants company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anticoagulants revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
According to APO Research, The global Anticoagulants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Anticoagulants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Anticoagulants include Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson., Genentech (Roche), Boehringer Ingelheim, Lilly, Daiichi Sankyo and Otsuka, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Anticoagulants, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anticoagulants, also provides the revenue of main regions and countries. Of the upcoming market potential for Anticoagulants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anticoagulants revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anticoagulants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Anticoagulants revenue, projected growth trends, production technology, application and end-user industry.
Anticoagulants segment by Company
- Sanofi
- Bristol-Myers Squibb
- Bayer
- Johnson & Johnson.
- Genentech (Roche)
- Boehringer Ingelheim
- Lilly
- Daiichi Sankyo
- Otsuka
- AstraZeneca
- Pfizer
- Aspen
- The Medicines Company
- Platelet Aggregation Inhibitors (PAI)
- Low-Molecular-Weight Heparin (LMWH)
- Direct Thrombin Inhibitor (DTI)
- Direct Factor Xa Inhibitors (DFXa)
- Vitamin K antagonists (VKA)
- Others
- VTE
- ACS/MI
- AF
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anticoagulants in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anticoagulants company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anticoagulants revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Anticoagulants Market by Type
1.2.1 Global Anticoagulants Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Platelet Aggregation Inhibitors (PAI)
1.2.3 Low-Molecular-Weight Heparin (LMWH)
1.2.4 Direct Thrombin Inhibitor (DTI)
1.2.5 Direct Factor Xa Inhibitors (DFXa)
1.2.6 Vitamin K antagonists (VKA)
1.2.7 Others
1.3 Anticoagulants Market by Application
1.3.1 Global Anticoagulants Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 VTE
1.3.3 ACS/MI
1.3.4 AF
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTICOAGULANTS MARKET DYNAMICS
2.1 Anticoagulants Industry Trends
2.2 Anticoagulants Industry Drivers
2.3 Anticoagulants Industry Opportunities and Challenges
2.4 Anticoagulants Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Anticoagulants Market Perspective (2019-2030)
3.2 Global Anticoagulants Growth Trends by Region
3.2.1 Global Anticoagulants Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Anticoagulants Market Size by Region (2019-2024)
3.2.3 Global Anticoagulants Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Anticoagulants Revenue by Players
4.1.1 Global Anticoagulants Revenue by Players (2019-2024)
4.1.2 Global Anticoagulants Revenue Market Share by Players (2019-2024)
4.1.3 Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Anticoagulants Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Anticoagulants Key Players Headquarters & Area Served
4.4 Global Anticoagulants Players, Product Type & Application
4.5 Global Anticoagulants Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Anticoagulants Market CR5 and HHI
4.6.2 Global Top 5 and 10 Anticoagulants Players Market Share by Revenue in 2023
4.6.3 2023 Anticoagulants Tier 1, Tier 2, and Tier
5 ANTICOAGULANTS MARKET SIZE BY TYPE
5.1 Global Anticoagulants Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Anticoagulants Revenue by Type (2019-2030)
5.3 Global Anticoagulants Revenue Market Share by Type (2019-2030)
6 ANTICOAGULANTS MARKET SIZE BY APPLICATION
6.1 Global Anticoagulants Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Anticoagulants Revenue by Application (2019-2030)
6.3 Global Anticoagulants Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Sanofi
7.1.1 Sanofi Comapny Information
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2019-2024)
7.1.4 Sanofi Anticoagulants Product Portfolio
7.1.5 Sanofi Recent Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Comapny Information
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2019-2024)
7.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
7.2.5 Bristol-Myers Squibb Recent Developments
7.3 Bayer
7.3.1 Bayer Comapny Information
7.3.2 Bayer Business Overview
7.3.3 Bayer Anticoagulants Revenue and Gross Margin (2019-2024)
7.3.4 Bayer Anticoagulants Product Portfolio
7.3.5 Bayer Recent Developments
7.4 Johnson & Johnson.
7.4.1 Johnson & Johnson. Comapny Information
7.4.2 Johnson & Johnson. Business Overview
7.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2019-2024)
7.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
7.4.5 Johnson & Johnson. Recent Developments
7.5 Genentech (Roche)
7.5.1 Genentech (Roche) Comapny Information
7.5.2 Genentech (Roche) Business Overview
7.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2019-2024)
7.5.4 Genentech (Roche) Anticoagulants Product Portfolio
7.5.5 Genentech (Roche) Recent Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Comapny Information
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2019-2024)
7.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
7.6.5 Boehringer Ingelheim Recent Developments
7.7 Lilly
7.7.1 Lilly Comapny Information
7.7.2 Lilly Business Overview
7.7.3 Lilly Anticoagulants Revenue and Gross Margin (2019-2024)
7.7.4 Lilly Anticoagulants Product Portfolio
7.7.5 Lilly Recent Developments
7.8 Daiichi Sankyo
7.8.1 Daiichi Sankyo Comapny Information
7.8.2 Daiichi Sankyo Business Overview
7.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2019-2024)
7.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
7.8.5 Daiichi Sankyo Recent Developments
7.9 Otsuka
7.9.1 Otsuka Comapny Information
7.9.2 Otsuka Business Overview
7.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2019-2024)
7.9.4 Otsuka Anticoagulants Product Portfolio
7.9.5 Otsuka Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Comapny Information
7.10.2 AstraZeneca Business Overview
7.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2019-2024)
7.10.4 AstraZeneca Anticoagulants Product Portfolio
7.10.5 AstraZeneca Recent Developments
7.11 Pfizer
7.11.1 Pfizer Comapny Information
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2019-2024)
7.11.4 Pfizer Anticoagulants Product Portfolio
7.11.5 Pfizer Recent Developments
7.12 Aspen
7.12.1 Aspen Comapny Information
7.12.2 Aspen Business Overview
7.12.3 Aspen Anticoagulants Revenue and Gross Margin (2019-2024)
7.12.4 Aspen Anticoagulants Product Portfolio
7.12.5 Aspen Recent Developments
7.13 The Medicines Company
7.13.1 The Medicines Company Comapny Information
7.13.2 The Medicines Company Business Overview
7.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2019-2024)
7.13.4 The Medicines Company Anticoagulants Product Portfolio
7.13.5 The Medicines Company Recent Developments
8 NORTH AMERICA
8.1 North America Anticoagulants Revenue (2019-2030)
8.2 North America Anticoagulants Revenue by Type (2019-2030)
8.2.1 North America Anticoagulants Revenue by Type (2019-2024)
8.2.2 North America Anticoagulants Revenue by Type (2025-2030)
8.3 North America Anticoagulants Revenue Share by Type (2019-2030)
8.4 North America Anticoagulants Revenue by Application (2019-2030)
8.4.1 North America Anticoagulants Revenue by Application (2019-2024)
8.4.2 North America Anticoagulants Revenue by Application (2025-2030)
8.5 North America Anticoagulants Revenue Share by Application (2019-2030)
8.6 North America Anticoagulants Revenue by Country
8.6.1 North America Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Anticoagulants Revenue by Country (2019-2024)
8.6.3 North America Anticoagulants Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Anticoagulants Revenue (2019-2030)
9.2 Europe Anticoagulants Revenue by Type (2019-2030)
9.2.1 Europe Anticoagulants Revenue by Type (2019-2024)
9.2.2 Europe Anticoagulants Revenue by Type (2025-2030)
9.3 Europe Anticoagulants Revenue Share by Type (2019-2030)
9.4 Europe Anticoagulants Revenue by Application (2019-2030)
9.4.1 Europe Anticoagulants Revenue by Application (2019-2024)
9.4.2 Europe Anticoagulants Revenue by Application (2025-2030)
9.5 Europe Anticoagulants Revenue Share by Application (2019-2030)
9.6 Europe Anticoagulants Revenue by Country
9.6.1 Europe Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Anticoagulants Revenue by Country (2019-2024)
9.6.3 Europe Anticoagulants Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Anticoagulants Revenue (2019-2030)
10.2 China Anticoagulants Revenue by Type (2019-2030)
10.2.1 China Anticoagulants Revenue by Type (2019-2024)
10.2.2 China Anticoagulants Revenue by Type (2025-2030)
10.3 China Anticoagulants Revenue Share by Type (2019-2030)
10.4 China Anticoagulants Revenue by Application (2019-2030)
10.4.1 China Anticoagulants Revenue by Application (2019-2024)
10.4.2 China Anticoagulants Revenue by Application (2025-2030)
10.5 China Anticoagulants Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Anticoagulants Revenue (2019-2030)
11.2 Asia Anticoagulants Revenue by Type (2019-2030)
11.2.1 Asia Anticoagulants Revenue by Type (2019-2024)
11.2.2 Asia Anticoagulants Revenue by Type (2025-2030)
11.3 Asia Anticoagulants Revenue Share by Type (2019-2030)
11.4 Asia Anticoagulants Revenue by Application (2019-2030)
11.4.1 Asia Anticoagulants Revenue by Application (2019-2024)
11.4.2 Asia Anticoagulants Revenue by Application (2025-2030)
11.5 Asia Anticoagulants Revenue Share by Application (2019-2030)
11.6 Asia Anticoagulants Revenue by Country
11.6.1 Asia Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Anticoagulants Revenue by Country (2019-2024)
11.6.3 Asia Anticoagulants Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Anticoagulants Revenue (2019-2030)
12.2 MEALA Anticoagulants Revenue by Type (2019-2030)
12.2.1 MEALA Anticoagulants Revenue by Type (2019-2024)
12.2.2 MEALA Anticoagulants Revenue by Type (2025-2030)
12.3 MEALA Anticoagulants Revenue Share by Type (2019-2030)
12.4 MEALA Anticoagulants Revenue by Application (2019-2030)
12.4.1 MEALA Anticoagulants Revenue by Application (2019-2024)
12.4.2 MEALA Anticoagulants Revenue by Application (2025-2030)
12.5 MEALA Anticoagulants Revenue Share by Application (2019-2030)
12.6 MEALA Anticoagulants Revenue by Country
12.6.1 MEALA Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Anticoagulants Revenue by Country (2019-2024)
12.6.3 MEALA Anticoagulants Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Anticoagulants Market by Type
1.2.1 Global Anticoagulants Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Platelet Aggregation Inhibitors (PAI)
1.2.3 Low-Molecular-Weight Heparin (LMWH)
1.2.4 Direct Thrombin Inhibitor (DTI)
1.2.5 Direct Factor Xa Inhibitors (DFXa)
1.2.6 Vitamin K antagonists (VKA)
1.2.7 Others
1.3 Anticoagulants Market by Application
1.3.1 Global Anticoagulants Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 VTE
1.3.3 ACS/MI
1.3.4 AF
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ANTICOAGULANTS MARKET DYNAMICS
2.1 Anticoagulants Industry Trends
2.2 Anticoagulants Industry Drivers
2.3 Anticoagulants Industry Opportunities and Challenges
2.4 Anticoagulants Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Anticoagulants Market Perspective (2019-2030)
3.2 Global Anticoagulants Growth Trends by Region
3.2.1 Global Anticoagulants Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Anticoagulants Market Size by Region (2019-2024)
3.2.3 Global Anticoagulants Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Anticoagulants Revenue by Players
4.1.1 Global Anticoagulants Revenue by Players (2019-2024)
4.1.2 Global Anticoagulants Revenue Market Share by Players (2019-2024)
4.1.3 Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Anticoagulants Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Anticoagulants Key Players Headquarters & Area Served
4.4 Global Anticoagulants Players, Product Type & Application
4.5 Global Anticoagulants Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Anticoagulants Market CR5 and HHI
4.6.2 Global Top 5 and 10 Anticoagulants Players Market Share by Revenue in 2023
4.6.3 2023 Anticoagulants Tier 1, Tier 2, and Tier
5 ANTICOAGULANTS MARKET SIZE BY TYPE
5.1 Global Anticoagulants Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Anticoagulants Revenue by Type (2019-2030)
5.3 Global Anticoagulants Revenue Market Share by Type (2019-2030)
6 ANTICOAGULANTS MARKET SIZE BY APPLICATION
6.1 Global Anticoagulants Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Anticoagulants Revenue by Application (2019-2030)
6.3 Global Anticoagulants Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Sanofi
7.1.1 Sanofi Comapny Information
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2019-2024)
7.1.4 Sanofi Anticoagulants Product Portfolio
7.1.5 Sanofi Recent Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Comapny Information
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2019-2024)
7.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
7.2.5 Bristol-Myers Squibb Recent Developments
7.3 Bayer
7.3.1 Bayer Comapny Information
7.3.2 Bayer Business Overview
7.3.3 Bayer Anticoagulants Revenue and Gross Margin (2019-2024)
7.3.4 Bayer Anticoagulants Product Portfolio
7.3.5 Bayer Recent Developments
7.4 Johnson & Johnson.
7.4.1 Johnson & Johnson. Comapny Information
7.4.2 Johnson & Johnson. Business Overview
7.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2019-2024)
7.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
7.4.5 Johnson & Johnson. Recent Developments
7.5 Genentech (Roche)
7.5.1 Genentech (Roche) Comapny Information
7.5.2 Genentech (Roche) Business Overview
7.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2019-2024)
7.5.4 Genentech (Roche) Anticoagulants Product Portfolio
7.5.5 Genentech (Roche) Recent Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Comapny Information
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2019-2024)
7.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
7.6.5 Boehringer Ingelheim Recent Developments
7.7 Lilly
7.7.1 Lilly Comapny Information
7.7.2 Lilly Business Overview
7.7.3 Lilly Anticoagulants Revenue and Gross Margin (2019-2024)
7.7.4 Lilly Anticoagulants Product Portfolio
7.7.5 Lilly Recent Developments
7.8 Daiichi Sankyo
7.8.1 Daiichi Sankyo Comapny Information
7.8.2 Daiichi Sankyo Business Overview
7.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2019-2024)
7.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
7.8.5 Daiichi Sankyo Recent Developments
7.9 Otsuka
7.9.1 Otsuka Comapny Information
7.9.2 Otsuka Business Overview
7.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2019-2024)
7.9.4 Otsuka Anticoagulants Product Portfolio
7.9.5 Otsuka Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Comapny Information
7.10.2 AstraZeneca Business Overview
7.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2019-2024)
7.10.4 AstraZeneca Anticoagulants Product Portfolio
7.10.5 AstraZeneca Recent Developments
7.11 Pfizer
7.11.1 Pfizer Comapny Information
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2019-2024)
7.11.4 Pfizer Anticoagulants Product Portfolio
7.11.5 Pfizer Recent Developments
7.12 Aspen
7.12.1 Aspen Comapny Information
7.12.2 Aspen Business Overview
7.12.3 Aspen Anticoagulants Revenue and Gross Margin (2019-2024)
7.12.4 Aspen Anticoagulants Product Portfolio
7.12.5 Aspen Recent Developments
7.13 The Medicines Company
7.13.1 The Medicines Company Comapny Information
7.13.2 The Medicines Company Business Overview
7.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2019-2024)
7.13.4 The Medicines Company Anticoagulants Product Portfolio
7.13.5 The Medicines Company Recent Developments
8 NORTH AMERICA
8.1 North America Anticoagulants Revenue (2019-2030)
8.2 North America Anticoagulants Revenue by Type (2019-2030)
8.2.1 North America Anticoagulants Revenue by Type (2019-2024)
8.2.2 North America Anticoagulants Revenue by Type (2025-2030)
8.3 North America Anticoagulants Revenue Share by Type (2019-2030)
8.4 North America Anticoagulants Revenue by Application (2019-2030)
8.4.1 North America Anticoagulants Revenue by Application (2019-2024)
8.4.2 North America Anticoagulants Revenue by Application (2025-2030)
8.5 North America Anticoagulants Revenue Share by Application (2019-2030)
8.6 North America Anticoagulants Revenue by Country
8.6.1 North America Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Anticoagulants Revenue by Country (2019-2024)
8.6.3 North America Anticoagulants Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Anticoagulants Revenue (2019-2030)
9.2 Europe Anticoagulants Revenue by Type (2019-2030)
9.2.1 Europe Anticoagulants Revenue by Type (2019-2024)
9.2.2 Europe Anticoagulants Revenue by Type (2025-2030)
9.3 Europe Anticoagulants Revenue Share by Type (2019-2030)
9.4 Europe Anticoagulants Revenue by Application (2019-2030)
9.4.1 Europe Anticoagulants Revenue by Application (2019-2024)
9.4.2 Europe Anticoagulants Revenue by Application (2025-2030)
9.5 Europe Anticoagulants Revenue Share by Application (2019-2030)
9.6 Europe Anticoagulants Revenue by Country
9.6.1 Europe Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Anticoagulants Revenue by Country (2019-2024)
9.6.3 Europe Anticoagulants Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Anticoagulants Revenue (2019-2030)
10.2 China Anticoagulants Revenue by Type (2019-2030)
10.2.1 China Anticoagulants Revenue by Type (2019-2024)
10.2.2 China Anticoagulants Revenue by Type (2025-2030)
10.3 China Anticoagulants Revenue Share by Type (2019-2030)
10.4 China Anticoagulants Revenue by Application (2019-2030)
10.4.1 China Anticoagulants Revenue by Application (2019-2024)
10.4.2 China Anticoagulants Revenue by Application (2025-2030)
10.5 China Anticoagulants Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Anticoagulants Revenue (2019-2030)
11.2 Asia Anticoagulants Revenue by Type (2019-2030)
11.2.1 Asia Anticoagulants Revenue by Type (2019-2024)
11.2.2 Asia Anticoagulants Revenue by Type (2025-2030)
11.3 Asia Anticoagulants Revenue Share by Type (2019-2030)
11.4 Asia Anticoagulants Revenue by Application (2019-2030)
11.4.1 Asia Anticoagulants Revenue by Application (2019-2024)
11.4.2 Asia Anticoagulants Revenue by Application (2025-2030)
11.5 Asia Anticoagulants Revenue Share by Application (2019-2030)
11.6 Asia Anticoagulants Revenue by Country
11.6.1 Asia Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Anticoagulants Revenue by Country (2019-2024)
11.6.3 Asia Anticoagulants Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Anticoagulants Revenue (2019-2030)
12.2 MEALA Anticoagulants Revenue by Type (2019-2030)
12.2.1 MEALA Anticoagulants Revenue by Type (2019-2024)
12.2.2 MEALA Anticoagulants Revenue by Type (2025-2030)
12.3 MEALA Anticoagulants Revenue Share by Type (2019-2030)
12.4 MEALA Anticoagulants Revenue by Application (2019-2030)
12.4.1 MEALA Anticoagulants Revenue by Application (2019-2024)
12.4.2 MEALA Anticoagulants Revenue by Application (2025-2030)
12.5 MEALA Anticoagulants Revenue Share by Application (2019-2030)
12.6 MEALA Anticoagulants Revenue by Country
12.6.1 MEALA Anticoagulants Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Anticoagulants Revenue by Country (2019-2024)
12.6.3 MEALA Anticoagulants Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Platelet Aggregation Inhibitors (PAI) Major Manufacturers
Table 2. Low-Molecular-Weight Heparin (LMWH) Major Manufacturers
Table 3. Direct Thrombin Inhibitor (DTI) Major Manufacturers
Table 4. Direct Factor Xa Inhibitors (DFXa) Major Manufacturers
Table 5. Vitamin K antagonists (VKA) Major Manufacturers
Table 6. Others Major Manufacturers
Table 7. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 8. VTE Major Manufacturers
Table 9. ACS/MI Major Manufacturers
Table 10. AF Major Manufacturers
Table 11. Others Major Manufacturers
Table 12. Anticoagulants Industry Trends
Table 13. Anticoagulants Industry Drivers
Table 14. Anticoagulants Industry Opportunities and Challenges
Table 15. Anticoagulants Industry Restraints
Table 16. Global Anticoagulants Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anticoagulants Market Size by Region (2019-2024) & (US$ Million)
Table 18. Global Anticoagulants Market Share by Region (2019-2024)
Table 19. Global Anticoagulants Market Size by Region (2025-2030) & (US$ Million)
Table 20. Global Anticoagulants Market Share by Region (2025-2030)
Table 21. Global Anticoagulants Revenue by Players (US$ Million) & (2019-2024)
Table 22. Global Anticoagulants Revenue Market Share by Players (2019-2024)
Table 23. Global Anticoagulants Key Players Ranking, 2022 VS 2023 VS 2024
Table 24. Global Anticoagulants Key Players Headquarters & Area Served
Table 25. Global Anticoagulants Players, Product Type & Application
Table 26. Global Anticoagulants Players Commercialization Time
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Anticoagulants by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 29. Global Anticoagulants Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 31. Global Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Table 32. Global Anticoagulants Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 33. Global Anticoagulants Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 34. Global Anticoagulants Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 36. Global Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Table 37. Global Anticoagulants Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 38. Global Anticoagulants Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 39. Sanofi Company Information
Table 40. Sanofi Business Overview
Table 41. Sanofi Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 42. Sanofi Anticoagulants Product Portfolio
Table 43. Sanofi Recent Development
Table 44. Bristol-Myers Squibb Company Information
Table 45. Bristol-Myers Squibb Business Overview
Table 46. Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 47. Bristol-Myers Squibb Anticoagulants Product Portfolio
Table 48. Bristol-Myers Squibb Recent Development
Table 49. Bayer Company Information
Table 50. Bayer Business Overview
Table 51. Bayer Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 52. Bayer Anticoagulants Product Portfolio
Table 53. Bayer Recent Development
Table 54. Johnson & Johnson. Company Information
Table 55. Johnson & Johnson. Business Overview
Table 56. Johnson & Johnson. Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 57. Johnson & Johnson. Anticoagulants Product Portfolio
Table 58. Johnson & Johnson. Recent Development
Table 59. Genentech (Roche) Company Information
Table 60. Genentech (Roche) Business Overview
Table 61. Genentech (Roche) Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 62. Genentech (Roche) Anticoagulants Product Portfolio
Table 63. Genentech (Roche) Recent Development
Table 64. Boehringer Ingelheim Company Information
Table 65. Boehringer Ingelheim Business Overview
Table 66. Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 67. Boehringer Ingelheim Anticoagulants Product Portfolio
Table 68. Boehringer Ingelheim Recent Development
Table 69. Lilly Company Information
Table 70. Lilly Business Overview
Table 71. Lilly Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 72. Lilly Anticoagulants Product Portfolio
Table 73. Lilly Recent Development
Table 74. Daiichi Sankyo Company Information
Table 75. Daiichi Sankyo Business Overview
Table 76. Daiichi Sankyo Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 77. Daiichi Sankyo Anticoagulants Product Portfolio
Table 78. Daiichi Sankyo Recent Development
Table 79. Otsuka Company Information
Table 80. Otsuka Business Overview
Table 81. Otsuka Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 82. Otsuka Anticoagulants Product Portfolio
Table 83. Otsuka Recent Development
Table 84. AstraZeneca Company Information
Table 85. AstraZeneca Business Overview
Table 86. AstraZeneca Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 87. AstraZeneca Anticoagulants Product Portfolio
Table 88. AstraZeneca Recent Development
Table 89. Pfizer Company Information
Table 90. Pfizer Business Overview
Table 91. Pfizer Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Pfizer Anticoagulants Product Portfolio
Table 93. Pfizer Recent Development
Table 94. Aspen Company Information
Table 95. Aspen Business Overview
Table 96. Aspen Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Aspen Anticoagulants Product Portfolio
Table 98. Aspen Recent Development
Table 99. The Medicines Company Company Information
Table 100. The Medicines Company Business Overview
Table 101. The Medicines Company Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. The Medicines Company Anticoagulants Product Portfolio
Table 103. The Medicines Company Recent Development
Table 104. North America Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 105. North America Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 106. North America Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 107. North America Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 108. North America Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 109. Europe Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 110. Europe Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 111. Europe Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 112. Europe Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 113. Europe Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 114. China Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 115. China Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 116. Asia Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 117. Asia Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 118. Asia Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 119. Asia Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 120. Asia Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 121. MEALA Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 122. MEALA Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 123. MEALA Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 124. MEALA Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 125. MEALA Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 126. Research Programs/Design for This Report
Table 127. Authors List of This Report
Table 128. Secondary Sources
Table 129. Primary Sources
Table 1. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Platelet Aggregation Inhibitors (PAI) Major Manufacturers
Table 2. Low-Molecular-Weight Heparin (LMWH) Major Manufacturers
Table 3. Direct Thrombin Inhibitor (DTI) Major Manufacturers
Table 4. Direct Factor Xa Inhibitors (DFXa) Major Manufacturers
Table 5. Vitamin K antagonists (VKA) Major Manufacturers
Table 6. Others Major Manufacturers
Table 7. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 8. VTE Major Manufacturers
Table 9. ACS/MI Major Manufacturers
Table 10. AF Major Manufacturers
Table 11. Others Major Manufacturers
Table 12. Anticoagulants Industry Trends
Table 13. Anticoagulants Industry Drivers
Table 14. Anticoagulants Industry Opportunities and Challenges
Table 15. Anticoagulants Industry Restraints
Table 16. Global Anticoagulants Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anticoagulants Market Size by Region (2019-2024) & (US$ Million)
Table 18. Global Anticoagulants Market Share by Region (2019-2024)
Table 19. Global Anticoagulants Market Size by Region (2025-2030) & (US$ Million)
Table 20. Global Anticoagulants Market Share by Region (2025-2030)
Table 21. Global Anticoagulants Revenue by Players (US$ Million) & (2019-2024)
Table 22. Global Anticoagulants Revenue Market Share by Players (2019-2024)
Table 23. Global Anticoagulants Key Players Ranking, 2022 VS 2023 VS 2024
Table 24. Global Anticoagulants Key Players Headquarters & Area Served
Table 25. Global Anticoagulants Players, Product Type & Application
Table 26. Global Anticoagulants Players Commercialization Time
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Anticoagulants by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 29. Global Anticoagulants Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 31. Global Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Table 32. Global Anticoagulants Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 33. Global Anticoagulants Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 34. Global Anticoagulants Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 36. Global Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Table 37. Global Anticoagulants Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 38. Global Anticoagulants Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 39. Sanofi Company Information
Table 40. Sanofi Business Overview
Table 41. Sanofi Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 42. Sanofi Anticoagulants Product Portfolio
Table 43. Sanofi Recent Development
Table 44. Bristol-Myers Squibb Company Information
Table 45. Bristol-Myers Squibb Business Overview
Table 46. Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 47. Bristol-Myers Squibb Anticoagulants Product Portfolio
Table 48. Bristol-Myers Squibb Recent Development
Table 49. Bayer Company Information
Table 50. Bayer Business Overview
Table 51. Bayer Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 52. Bayer Anticoagulants Product Portfolio
Table 53. Bayer Recent Development
Table 54. Johnson & Johnson. Company Information
Table 55. Johnson & Johnson. Business Overview
Table 56. Johnson & Johnson. Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 57. Johnson & Johnson. Anticoagulants Product Portfolio
Table 58. Johnson & Johnson. Recent Development
Table 59. Genentech (Roche) Company Information
Table 60. Genentech (Roche) Business Overview
Table 61. Genentech (Roche) Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 62. Genentech (Roche) Anticoagulants Product Portfolio
Table 63. Genentech (Roche) Recent Development
Table 64. Boehringer Ingelheim Company Information
Table 65. Boehringer Ingelheim Business Overview
Table 66. Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 67. Boehringer Ingelheim Anticoagulants Product Portfolio
Table 68. Boehringer Ingelheim Recent Development
Table 69. Lilly Company Information
Table 70. Lilly Business Overview
Table 71. Lilly Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 72. Lilly Anticoagulants Product Portfolio
Table 73. Lilly Recent Development
Table 74. Daiichi Sankyo Company Information
Table 75. Daiichi Sankyo Business Overview
Table 76. Daiichi Sankyo Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 77. Daiichi Sankyo Anticoagulants Product Portfolio
Table 78. Daiichi Sankyo Recent Development
Table 79. Otsuka Company Information
Table 80. Otsuka Business Overview
Table 81. Otsuka Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 82. Otsuka Anticoagulants Product Portfolio
Table 83. Otsuka Recent Development
Table 84. AstraZeneca Company Information
Table 85. AstraZeneca Business Overview
Table 86. AstraZeneca Anticoagulants Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 87. AstraZeneca Anticoagulants Product Portfolio
Table 88. AstraZeneca Recent Development
Table 89. Pfizer Company Information
Table 90. Pfizer Business Overview
Table 91. Pfizer Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Pfizer Anticoagulants Product Portfolio
Table 93. Pfizer Recent Development
Table 94. Aspen Company Information
Table 95. Aspen Business Overview
Table 96. Aspen Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Aspen Anticoagulants Product Portfolio
Table 98. Aspen Recent Development
Table 99. The Medicines Company Company Information
Table 100. The Medicines Company Business Overview
Table 101. The Medicines Company Anticoagulants Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. The Medicines Company Anticoagulants Product Portfolio
Table 103. The Medicines Company Recent Development
Table 104. North America Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 105. North America Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 106. North America Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 107. North America Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 108. North America Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 109. Europe Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 110. Europe Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 111. Europe Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 112. Europe Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 113. Europe Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 114. China Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 115. China Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 116. Asia Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 117. Asia Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 118. Asia Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 119. Asia Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 120. Asia Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 121. MEALA Anticoagulants Revenue by Type (2019-2024) & (US$ Million)
Table 122. MEALA Anticoagulants Revenue by Application (2019-2024) & (US$ Million)
Table 123. MEALA Anticoagulants Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 124. MEALA Anticoagulants Revenue by Country (2019-2024) & (US$ Million)
Table 125. MEALA Anticoagulants Revenue by Country (2025-2030) & (US$ Million)
Table 126. Research Programs/Design for This Report
Table 127. Authors List of This Report
Table 128. Secondary Sources
Table 129. Primary Sources
LIST OF FIGURES
Figure 1. Anticoagulants Product Picture
Figure 2. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Anticoagulants Market Size Share 2019 VS 2023 VS 2030
Figure 4. Platelet Aggregation Inhibitors (PAI) Picture
Figure 5. Low-Molecular-Weight Heparin (LMWH) Picture
Figure 6. Direct Thrombin Inhibitor (DTI) Picture
Figure 7. Direct Factor Xa Inhibitors (DFXa) Picture
Figure 8. Vitamin K antagonists (VKA) Picture
Figure 9. Others Picture
Figure 10. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Anticoagulants Market Size Share 2019 VS 2023 VS 2030
Figure 12. VTE Picture
Figure 13. ACS/MI Picture
Figure 14. AF Picture
Figure 15. Others Picture
Figure 16. Global Anticoagulants Market Size (US$ Million) & (2019-2030)
Figure 17. Global Anticoagulants Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Anticoagulants Market Share by Region: 2019 VS 2023 VS 2030
Figure 19. Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2023
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 21. Global Anticoagulants Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Anticoagulants Revenue Market Share 2019 VS 2023 VS 2030
Figure 23. Global Anticoagulants Revenue Market Share by Type (2019-2030)
Figure 24. Global Anticoagulants Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 25. Global Anticoagulants Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 26. Global Anticoagulants Revenue Market Share by Application (2019-2030)
Figure 27. North America Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 28. North America Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 29. North America Anticoagulants Revenue Share by Type (2019-2030)
Figure 30. North America Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 31. North America Anticoagulants Revenue Share by Application (2019-2030)
Figure 32. North America Anticoagulants Revenue Share by Country (2019-2030)
Figure 33. United States Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 34. Canada Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 35. Europe Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 36. Europe Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 37. Europe Anticoagulants Revenue Share by Type (2019-2030)
Figure 38. Europe Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 39. Europe Anticoagulants Revenue Share by Application (2019-2030)
Figure 40. Europe Anticoagulants Revenue Share by Country (2019-2030)
Figure 41. Germany Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. France Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. U.K. Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Italy Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Russia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 46. Nordic Countries Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 47. China Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 48. China Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 49. China Anticoagulants Revenue Share by Type (2019-2030)
Figure 50. China Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 51. China Anticoagulants Revenue Share by Application (2019-2030)
Figure 52. Asia Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 53. Asia Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 54. Asia Anticoagulants Revenue Share by Type (2019-2030)
Figure 55. Asia Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 56. Asia Anticoagulants Revenue Share by Application (2019-2030)
Figure 57. Asia Anticoagulants Revenue Share by Country (2019-2030)
Figure 58. Japan Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. South Korea Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. India Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. Australia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. China Taiwan Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 63. Southeast Asia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 64. MEALA Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 65. MEALA Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 66. MEALA Anticoagulants Revenue Share by Type (2019-2030)
Figure 67. MEALA Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 68. MEALA Anticoagulants Revenue Share by Application (2019-2030)
Figure 69. MEALA Anticoagulants Revenue Share by Country (2019-2030)
Figure 70. Mexico Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. South Korea Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Brazil Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Israel Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Argentina Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Colombia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Turkey Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. Saudi Arabia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 78. UAE Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 79. Years Considered
Figure 80. Research Process
Figure 81. Key Executives Interviewed
Figure 1. Anticoagulants Product Picture
Figure 2. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Anticoagulants Market Size Share 2019 VS 2023 VS 2030
Figure 4. Platelet Aggregation Inhibitors (PAI) Picture
Figure 5. Low-Molecular-Weight Heparin (LMWH) Picture
Figure 6. Direct Thrombin Inhibitor (DTI) Picture
Figure 7. Direct Factor Xa Inhibitors (DFXa) Picture
Figure 8. Vitamin K antagonists (VKA) Picture
Figure 9. Others Picture
Figure 10. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Anticoagulants Market Size Share 2019 VS 2023 VS 2030
Figure 12. VTE Picture
Figure 13. ACS/MI Picture
Figure 14. AF Picture
Figure 15. Others Picture
Figure 16. Global Anticoagulants Market Size (US$ Million) & (2019-2030)
Figure 17. Global Anticoagulants Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Anticoagulants Market Share by Region: 2019 VS 2023 VS 2030
Figure 19. Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2023
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 21. Global Anticoagulants Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Anticoagulants Revenue Market Share 2019 VS 2023 VS 2030
Figure 23. Global Anticoagulants Revenue Market Share by Type (2019-2030)
Figure 24. Global Anticoagulants Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 25. Global Anticoagulants Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 26. Global Anticoagulants Revenue Market Share by Application (2019-2030)
Figure 27. North America Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 28. North America Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 29. North America Anticoagulants Revenue Share by Type (2019-2030)
Figure 30. North America Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 31. North America Anticoagulants Revenue Share by Application (2019-2030)
Figure 32. North America Anticoagulants Revenue Share by Country (2019-2030)
Figure 33. United States Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 34. Canada Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 35. Europe Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 36. Europe Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 37. Europe Anticoagulants Revenue Share by Type (2019-2030)
Figure 38. Europe Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 39. Europe Anticoagulants Revenue Share by Application (2019-2030)
Figure 40. Europe Anticoagulants Revenue Share by Country (2019-2030)
Figure 41. Germany Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. France Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. U.K. Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Italy Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Russia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 46. Nordic Countries Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 47. China Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 48. China Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 49. China Anticoagulants Revenue Share by Type (2019-2030)
Figure 50. China Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 51. China Anticoagulants Revenue Share by Application (2019-2030)
Figure 52. Asia Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 53. Asia Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 54. Asia Anticoagulants Revenue Share by Type (2019-2030)
Figure 55. Asia Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 56. Asia Anticoagulants Revenue Share by Application (2019-2030)
Figure 57. Asia Anticoagulants Revenue Share by Country (2019-2030)
Figure 58. Japan Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. South Korea Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. India Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. Australia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. China Taiwan Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 63. Southeast Asia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 64. MEALA Anticoagulants Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 65. MEALA Anticoagulants Revenue by Type (2025-2030) & (US$ Million)
Figure 66. MEALA Anticoagulants Revenue Share by Type (2019-2030)
Figure 67. MEALA Anticoagulants Revenue by Application (2025-2030) & (US$ Million)
Figure 68. MEALA Anticoagulants Revenue Share by Application (2019-2030)
Figure 69. MEALA Anticoagulants Revenue Share by Country (2019-2030)
Figure 70. Mexico Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. South Korea Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Brazil Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Israel Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Argentina Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Colombia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Turkey Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. Saudi Arabia Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 78. UAE Anticoagulants Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 79. Years Considered
Figure 80. Research Process
Figure 81. Key Executives Interviewed
